Actively Recruiting
RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care
Led by Region Stockholm · Updated on 2025-09-23
1600
Participants Needed
7
Research Sites
130 weeks
Total Duration
On this page
Sponsors
R
Region Stockholm
Lead Sponsor
K
Karolinska Institutet
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if drug dapagliflozin, a sodium-glucose transport-2 inhibitor, works to treat atrial fibrillation in adults. The main question it aims to answer is: • Does the drug dapagliflozin reduce the recurrence rate of atrial fibrillation? Researchers will compare drug dapagliflozin to standard therapy to see if drug dapagliflozin reduce the recurrence of atrial fibrillation. Persons with atrial fibrillation who are planned for an electric cardioversion will: * Take the drug dapagliflozin, or no drug, once a day for a maximum of 56 days * Undergo a planned electric cardioversion of the atrial fibrillation * Record the rhythm with a hand-held device that transmits the signal to researchers during the study period, but no longer than for 56 days
CONDITIONS
Official Title
RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with atrial fibrillation on ECG who are planned for electrical cardioversion within 7 to 26 days from inclusion
- Age 55 years or older
- Provided written informed consent
You will not qualify if you...
- Current treatment with an SGLT2 inhibitor
- Prior or current diagnosis of heart failure
- Type 1 diabetes mellitus
- Estimated glomerular filtration rate (eGFR) less than 25 mL/min/1.73m2
- Pulmonary vein isolation within preceding 3 months or planned during study period (56 days)
- Contraindications to SGLT2 inhibitors
- Any condition or circumstance in which the patient should not participate according to the study investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Linköping university hosptial
Linköping, Sweden, 58225
Not Yet Recruiting
2
Örebro University hospital
Örebro, Sweden, 70382
Actively Recruiting
3
Södersjukhuset
Stockholm, Sweden, 11861
Not Yet Recruiting
4
Karolinska University Hospital
Stockholm, Sweden, 14186
Actively Recruiting
5
Danderyds Hospital
Stockholm, Sweden, 18527
Not Yet Recruiting
6
Norrlands universitetssjukhus
Umeå, Sweden, 90185
Not Yet Recruiting
7
Akademiska sjukhuset
Uppsala, Sweden, 75389
Not Yet Recruiting
Research Team
K
Karolina Szummer, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here